早产儿视网膜病变玻璃体腔注射贝伐珠单抗后的认知结局:前瞻性队列4至6年结果
这项前瞻性队列研究纳入186名3至6岁儿童,最终分析101名,比较无ROP早产儿、无需治疗ROP、IVB单药、IVB联合激光及激光单药组的认知结局。结果显示各组全量表智商在基线和末次随访时均无显著差异,IVB单药组认知结局与其他早产儿相当。
要点
- IVB单药治疗ROP的儿童在4.5岁至6岁以上认知结局与无IVB早产儿相当。
- IVB联合激光组在4.5岁时严重认知损害(FSIQ<70)比例高于其他组,但末次随访时组间无差异。
- 校正混杂因素后,IVB与基线和末次随访的FSIQ均无关联。
核心结论
- 4.5岁至6岁以上,接受IVB单药治疗的儿童认知结局与无IVB早产儿相当。
- IVB联合激光组在4.5岁时严重认知损害更常见,但末次随访时组间无差异。
研究设计与样本
- 前瞻性队列研究,单中心,纳入186名3至6岁儿童,最终分析101名。
- 分组:无ROP早产儿(组1)、无需治疗ROP(组2)、IVB单药(组3)、IVB联合激光(组4)、激光单药(组5)。
- 采用韦氏幼儿及学龄前智力量表评估全量表智商(FSIQ),基线和每年随访1-2年。
主要发现
- 认知评估年龄基线为4.5-4.9岁,末次随访为6.1-7.0岁。
- 校正性别、Apgar评分、新生儿不良事件和机械通气天数后,IVB与基线和末次随访FSIQ均无关联。
关键数值与推荐
- 严重认知损害定义为FSIQ<70。
临床怎么用
- IVB单药治疗ROP未显示对4.5至6岁以上认知结局的不良影响。
- IVB联合激光治疗者需关注早期严重认知损害风险,但长期差异不显著。
局限性
- 单中心研究,最终分析样本量101名,可能存在选择偏倚。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the long-term cognitive outcomes in children who underwent intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP). DESIGN: Prospective cohort study. METHODS: This single-center study enrolled 186 children between 3 and 6 years of age and included 101 children in the final analysis: premature without ROP (group 1), ROP not needing treatment (group 2), IVB monotherapy (group 3), IVB plus laser therapy (group 4), and laser monotherapy (group 5). The Full-Scale Intelligence Quotient (FSIQ) was evaluated by the Wechsler Preschool and Primary Scale of Intelligence Test at baseline and then annually for 1-2 years and compared among groups. RESULTS: The age at cognitive evaluation was 4.5-4.9 years at baseline and 6.1-7.0 years at the last follow-up. The FSIQ was comparable among the groups at both time points (P = .08 and .50, respectively). Severe cognitive impairment (FSIQ < 70) was more common in group 4 at baseline (4%, 22%, 13%, 33%, and 0% in groups 1-5, respectively; P = .03) but did not differ among the groups at the last follow-up (6%, 0%, 4%, 22%, and 0%; P = .22). After adjusting for sex, Apgar score, neonatal adverse events, and days on mechanical ventilation, IVB was not associated with FSIQ either at baseline or at the last follow-up. CONCLUSIONS: At 4.5 to beyond 6 years of age, children who underwent IVB monotherapy had comparable cognitive outcomes compared to the other premature children without prior IVB. Children who underwent IVB plus laser showed higher severe cognitive impairment at 4.5 years of age.
引用
- Chou HD, Shih CP, Huang YS, et al. Cognitive Outcomes Following Intravitreal Bevacizumab for Retinopathy of Prematurity: 4- to 6-Year Outcomes in a Prospective Cohort. Am J Ophthalmol. 2021. PMID: 34283975. doi:10.1016/j.ajo.2021.06.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。